Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation
Published Date:Nov 20 2014
Source:J Child Neurol. 30(10):1275-1280.
Corporate Authors:MD STAR
Keywords:Adrenal Cortex Hormones
Age Of Onset
Duchenne Muscular Dystrophy
Muscular Dystrophy, Duchenne
Proportional Hazards Models
Pubmed Central ID:PMC4439376
Funding:CC999999/Intramural CDC HHS/United States
U01 DD000191/DD/NCBDD CDC HHS/United States
5 U01 DD000191/DD/NCBDD CDC HHS/United States
Description:This population-based study examines the association between corticosteroid treatment and time to loss of ambulation, stratifying by treatment duration (short: 0.25-3 years, long: >3 years), among 477 Duchenne muscular dystrophy cases identified by the Muscular Dystrophy Surveillance Tracking and Research Network (MDSTARnet). Those cases who received short-term corticosteroid treatment had a time to loss of ambulation that was 0.8 years shorter (t test) and an annual risk of losing ambulation 77% higher than the untreated (Cox regression). Conversely, cases who received long-term corticosteroid treatment had a time to loss of ambulation that was 2 years longer and an annual risk of losing ambulation 82% lower than the untreated, up to age 11 years; after which the risks were not statistically different. The relationship of corticosteroids and time to loss of ambulation is more complex than depicted by previous studies limited to treatment responders or subjects who lost ambulation during study follow-up.
application/octet-stream image/gif image/jpeg image/gif image/jpeg
You May Also Like: